DRUG REGULATORY AUTHORITY OF PAKISTAN
DIVISION OF QUALITY ASSURANCE & LABORATORY TESTING

MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº II/S/10-25-90

DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

Date: 15th October, 2025

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Drug, water & food testing Laboratory, Gilgit Baltistan informed the Drug Regulatory Authority of Pakistan that the sample of below mentioned drug product has been declared as '***Substandard***'.

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	**Tablet Cloferd 50 mg** Each film coated tablet contains: Clomiphene Citrate …….. 50mg (Reg. # 066676)	6926	M/s Medizan Laboratories (Pvt) Ltd. Plot No 313 Industrial Triangle Kahuta Road Islamabad. (DML # 000572)	The Sample is declared as **"Sub-Standard"** on the basis of Dissolution Test.

Risk Statement:

Clomiphene Citrate is indicated for the treatment of **female infertility and ovulatory disorders**. Use of a substandard product with inadequate dissolution may lead to **reduced therapeutic efficacy**, resulting in **failure of ovulation induction, delayed conception, or treatment frustration** in women of reproductive age undergoing fertility management. Timely identification and withdrawal of the affected batch are essential to prevent therapeutic failure and ensure patient safety.

Action initiated: -

The field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores: -

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

DRAP, Islamabad
+92 051 9255969
gsms@dra.gov.pk

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موثر اور معیاری اشیائے علاج